25 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise women not to breastfeed during IBRANCE
8-K
EX-99.1
ARVN
Arvinas Inc
6 Dec 23
Regulation FD Disclosure
7:01am
women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing
8-K
EX-99.1
2knxv891
8 Dec 22
Regulation FD Disclosure
8:19am
8-K
EX-99.1
q52bapd
22 Nov 22
Regulation FD Disclosure
5:26pm
8-K
EX-99.1
k9eg8grd0fygbk5vi0g4
21 Nov 22
Regulation FD Disclosure
6:16pm
8-K
EX-99.1
kx69bgj9luxf62 1icg4
10 Dec 21
Regulation FD Disclosure
8:16am
8-K
EX-99.1
713c3dr3xxu5tzb
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-99.1
ix3 rp4if4t
16 Mar 20
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:01am
8-K
EX-99.1
qqy6pxjeu52zsyu5
4 Nov 19
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
5:10pm
8-K
EX-99.1
irvqsif oij6
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am
8-K
EX-99.2
4j9sxp4 la
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am
8-K
EX-99.1
bni7irz0157l97jc
1 Apr 19
Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
4:52pm